SCHEMBL5657152

SCHEMBL5657152

N#CCc1ccc2nsnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 4/20 0.44
PTPN1 P18031 2/20 0.40
TXNRD1 Q16881 1/20 0.38
TXNRD3 Q86VQ6 1/20 0.38
TXNRD2 Q9NNW7 1/20 0.38
ENPP2 Q13822 1/20 0.37
KDM4E B2RXH2 3/20 0.35
TDP1 Q9NUW8 1/20 0.35
MMP3 P08254 1/20 0.35
ALDH1A1 P00352 2/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
LMNA P02545 2/20 0.33
RECQL P46063 2/20 0.33
MEN1 O00255 2/20 0.33
BLM P54132 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722040 0.74 TGFBR1 (0.47) ENPP2KDM4ETDP1MMP3MEN1
SCHEMBL257319 0.74 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL4682270 0.74 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL3678157 0.73 MAPT (0.49) ENPP2KDM4ETDP1MMP3ALDH1A1
SCHEMBL5654842 0.72 ALDH1A1 (0.47) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL2728002 0.69 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL12595077 0.69 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL8256195 0.69 PTPN11 (0.44) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL8724132 0.69 PTPN11 (0.48) PTPN11PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL8184154 0.69 PTPN11 (0.47) PTPN11PTPN1TXNRD1TXNRD3TXNRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186730-B2 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2007-03-06 US disclosed
EP-1392686-B1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2006-10-18 EP disclosed
EP-1343780-B1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2006-09-20 EP disclosed
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-10-07 US disclosed
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections SMITHKLINE BEECHAM P.L.C. (GB) 2004-04-22 US disclosed
EP-1392686-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-03 EP disclosed
EP-1343780-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2003-09-17 EP disclosed
WO-2002096907-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-05 WO disclosed
WO-2002050061-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials NRDC, NUCB2, ASNS PTPN11 4477/4885PTPN1 4239/4885TXNRD1 1539/4885
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections MYD88, THPO, PIGO PTPN11 3774/4885PTPN1 3631/4885TXNRD1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.